diss_wolf_theresa.pdf (2449 KB) - Ernst-Moritz-Arndt-Universität ...

148 Literatur
Hsieh, H.M., Swerdlow, N.R. & Braff, D.L. (2006). Effects of background and prepulse
characteristics on prepulse inhibition and facilitation: implications for neuropsychiatric
research. Biological Psychiatry, 59(6), 555-559
Innocenti, G.M., Ansermet, F. & Parnas, J. (2003). Schizophrenia, neurodevelopment and
corpus callosum. Molecular Psychiatry, 8 (3), 261-274
Jablensky, A. (2000). Epidemiology of schizophrenia: the global burden of disease and disability.
European Archives of Clinical Neuroscience, 250, 274-285
Jennings, P.D., Schell, A.M., Filion, D.L. & Dawson, M.E. (1996). Tracking early and late
stages of information processing: contributions of startle eyeblink reflex modification.
Psychophysiology, 33, 148-155
Jovanovic, T., Szilagyi, S., Chakravorty, S., Fiallos, A.M., Lewison, B.J., Parwani, A.,
Schwartz, M.P., Gonzenbach, S., Rotrosen, J.P. & Duncan, E.J. (2004). Menstrual
cycle phase effects on prepulse inhibition of acoustic startle. Psychophysiology, 41,
401-406
Karper, L.P., Freeman, G.K., Grillon, C., Morgan III, C.A., Charney, D.S. & Krystal, J.H.
(1996). Preliminary evidence of an association between sensorimotor gating and
distractibility in psychosis. Journal of neuropsychiatry and clinical neurosciences,
8(1), 60-66
Kay, S.R., Fiszbein, A. & Opler, L.A. (1987). The positive and negative syndrome scale
(PANSS) for schizophrenia. Schizophrenia Bulletin, 13, 261-276
Keefe, R.S.E., Silva, S.G., Perkins, D.O. & Lieberman, J.A. (1999). The effects of atypical
antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and
meta-analysis. Schizophrenia Bulletin, 25(2), 201-222
Keefe, R.S., Bilder, R.M., Davis, S.M., Harvey, P.D., Davis, S.M., Palmer, B.W., Gold,
J.M., Meltzer, H.Y., Green, M.F., Miller, D.D., Canive, J.M., Adler, L.W.,
Manschreck, T.C., Swartz, M.S., Rosenheck, R.A., Perkins, D.O., Walker, T.M.,
Stroup, T.S., McEvoy, J.P. & Lieberman, J.A. (2006a). Baseline neurocognitive
deficits in the CATIE schizophrenia trial. Neuropsychopharmacology, 31(9), 2033-
2046
Keefe, R.S., Seidman, L.J., Christensen, B.K., Hamer, R.M., Sharma, T., Sitskoorn, M.M.,
Rock, S.L., Woolson, S., Tohen, M., Tollefson, G.D., Sanger, T.M. & Lieberman,